For
immediate release
|
22 March
2024
|
ANGLE plc ("the
Company")
PARSORTIX SYSTEM AND ASSAYS
BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER
CONFERENCE
ANGLE presenting two posters
highlighting the utility of the Company's new Portrait+ CTC
Staining Kit and Portrait HER2 assay
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology, is pleased to announce its participation at
the 14th European Breast Cancer Conference (EBCC)
being held in Milan, Italy on 20 to 22 March 2024.
EBCC is focused on
multidisciplinary, high-quality clinical and translational
research, with an emphasis on innovation and technology in the
management of breast cancer. The conference is attended by
researchers, physicians, patient advocates and industry
representatives providing sales, partnership and collaboration
opportunities.
ANGLE is presenting two posters at
the conference:
1. Integrating isolation using label-independent
microfluidics and advanced staining for comprehensive Circulating
Tumour Cell Analysis
ANGLE's Parsortix® system
and Portrait®+ CTC Staining Kit together provide an
optimised, efficient, and standardised solution for the harvest and
characterisation, via immunofluorescence (IF) staining, of a
diverse range of CTC phenotypes. In the presented data, half of the
CTC-positive breast cancer patient blood samples contained only
mesenchymal CTCs, while half had a combination of both epithelial and mesenchymal CTCs. Patients
with purely mesenchymal CTCs would have been missed by
epitope-dependent systems. This is important because mesenchymal
CTCs or CTCs undergoing epithelial-to-mesenchymal transition are
clinically significant, playing a critical role in cancer
progression, treatment resistance and metastasis.
CTC clusters harvested by the
Parsortix system were observed in 75% of the CTC-positive patients
which is crucial given that CTC clusters have been shown to have up
to 100 times the increased metastatic potential compared to single
CTCs. The Parsortix cassette's unique design is suited to capturing
and harvesting clusters which is often difficult with other CTC
systems.
The study results highlight the
importance of using ANGLE's Parsortix system combined with the
Company's Portrait+ CTC Staining Kit, to enable the isolation and
analysis of a range of CTC phenotypes and CTC clusters, both of
which are important in cancer progression and metastasis.
2. Interrogating HER2 status in Circulating Tumour Cells
isolated using the Parsortix® system from Metastatic
Breast Cancer patients
The diagnosis and treatment of
breast cancer is currently guided by the evaluation of human
epidermal growth factor receptor 2 (HER2) status in tissue
biopsies. However, a tissue biopsy is invasive, is at a single
point in time and, with little opportunity for repeat testing, can
become out of date. The longitudinal monitoring of HER2 expression
from blood is possible through minimally invasive CTC-based liquid
biopsy techniques. ANGLE has developed an IF assay for HER2 protein
identification on CTCs isolated and harvested using the Parsortix
system from the peripheral blood of metastatic breast cancer (MBC)
patients.
Results from an in-house study in 26
patients found that CTCs overexpressing HER2 were present at
similar levels in patients that had HER2+ or HER2- tumours by
primary tissue biopsy. HER2 status of CTCs was also dynamic,
changing over time in 37% of CTC positive donors which is
unsurprising given that temporal changes in HER2 tissue status are
also well documented in the literature. One third-party study of
575 breast cancer patients similarly found that 38% had changed
HER2 status from the original primary tissue biopsy to the
metastatic tissue biopsy, at disease recurrence. These initial
results using Parsortix-based harvest of CTCs demonstrate how the
HER2 status between primary tumours and CTCs can diverge, and that
analysis of HER2 expression on CTCs has the potential to help guide
clinical decision making in MBC patients, allowing for regular
monitoring and tracking of treatment and/or disease
progression.
ANGLE Chief Scientific Officer, Karen Miller,
commented:
"We are delighted to have had two
posters presented at the EBCC conference. The results of these
studies further demonstrate the potential utility of ANGLE's
sample-to-answer Parsortix system and Portrait imaging assays for
reliable and repeatable assessment of biomarkers in a range of
solid tumours, including breast. We look forward to discussions
with translational researchers and industry representatives at this
conference to explore opportunities for sales, collaboration, and
partnerships."
For
further information:
ANGLE plc
|
+44
(0) 1483 343434
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
Berenberg (NOMAD and Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
For Research Use Only. Not for use
in diagnostic procedures.
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting
technology known as the Parsortix® PC1 System enables
complete downstream analysis of the sample including whole cell
imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system and associated
consumables. The clinical services business is offered through
ANGLE's GCP-compliant laboratories in the UK. Services include
custom made assay development and clinical trial testing for
pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com